News
10h
MedPage Today on MSNThe Wealth and Complexity of Treatment Options for Relapsed/Refractory Multiple MyelomaFor patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with ...
Multiple myeloma, a treatable but incurable blood cancer, is rising sharply in India, especially among those over 60. Dr.
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according ...
New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...
In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...
Drugs that treat a similar plasma cell disease, multiple myeloma, can sometimes be effective in people with AL amyloidosis. By far, the most important of these drugs is daratumumab (Darzalex), a ...
Background: Amyloidosis, particularly light-chain (AL) amyloidosis, is a rare but serious complication of multiple myeloma (MM) that can significantly impact cardiac function, particularly among ...
"We want to cure multiple myeloma, one way or another," S. Vincent Rajkumar, MD, chair of the Myeloma Amyloidosis Dysproteinemia Group at Mayo Clinic in Rochester, Minnesota, told MedPage Today ...
The two conditions that AL amyloidosis can overlap with is most commonly MGAS, or a monoclonal gammopathy, and then less commonly, but more severe, would be multiple myeloma.
Ríos-Tamayo R, Krsnik I, Gómez-Bueno M, et al. AL amyloidosis and multiple myeloma: A complex scenario in which cardiac involvement remains the key prognostic factor. Life (Basel) . 2023;13(7):1518.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results